The Impact Of Developmental Haemostasis On The Pharmacokinetics And Pharmacodynamics Of Heparin In Children.
Funder
National Health and Medical Research Council
Funding Amount
$283,676.00
Summary
Unfractionated Heparin (UFH) is the most commonly used anticoagulant (blood thinning drug) in children. Despite this, the clinical evidence, in terms of reported treatment failures and bleeding complications, suggests the drug is used suboptimally in children compared to adults.This likely relfects the lack of specific studies of UFH in children. This study will, for the first time, define the pharmacokinetics-dynamics of UFH in children, allowing age-specific protocols to be developed. Pharmaco ....Unfractionated Heparin (UFH) is the most commonly used anticoagulant (blood thinning drug) in children. Despite this, the clinical evidence, in terms of reported treatment failures and bleeding complications, suggests the drug is used suboptimally in children compared to adults.This likely relfects the lack of specific studies of UFH in children. This study will, for the first time, define the pharmacokinetics-dynamics of UFH in children, allowing age-specific protocols to be developed. Pharmacological modelling of this data will likely have implications for the use of other anticoagulants in children.Read moreRead less
Improving The Quantity, Quality, Relevance And Conduct Of Clinical Trials Of Medicines In Children.
Funder
National Health and Medical Research Council
Funding Amount
$102,576.00
Summary
I am a specialist clinical trials pharmacist focussed on the challenges associated with the conduct of medicinal trials in children. My intention is to collect evidence to determine the best strategies for improving the quantity, quality and relevance of clinical trials in children. This will help to ensure safe and effective age-appropriate drug therapies for children and improve the health outcomes of our children.
The Role Of Microtubule Composition In The Efficacy Of Antimicrotubule Agents In Paediatric Malignancy
Funder
National Health and Medical Research Council
Funding Amount
$173,380.00
Summary
To enhance the management of both childhood and adult cancers improved understanding of the processes responsible for tumour aggressiveness and drug resistance are required. Microtubules are important structural components of cells which are crucial for normal cell division. This makes microtubules excellent targets for anticancer drugs which can disrupt microtubules and kill cancer cells. This proposal will identify whether the microtubule composition of a tumour cell will predict for the aggre ....To enhance the management of both childhood and adult cancers improved understanding of the processes responsible for tumour aggressiveness and drug resistance are required. Microtubules are important structural components of cells which are crucial for normal cell division. This makes microtubules excellent targets for anticancer drugs which can disrupt microtubules and kill cancer cells. This proposal will identify whether the microtubule composition of a tumour cell will predict for the aggressiveness of certain cancers, and whether this influences which tumours will respond to the vinca alkaloids. The vinca alkaloids are an important class of natural product drugs which disrupt microtubules and are particularly effective in the treatment of adult and childhood cancers. Unfortunately, some cancer cells fail to respond to this treatment due to the development of drug resistance. This proposal addresses vinca alkaloid resistance in children?s cancer and will determine why certain cancer cells fail treatment. Furthermore, this study will identify the role of certain components of microtubules that appear to be related to drug resistance in leukaemia and neuroblastoma cells and whose role is unknown. Chemotherapeutic drugs, such as the vinca alkaloids, are important in the treatment of cancer and knowledge about their interaction with their cellular target will improve the design of new drugs and treatment outcome.Read moreRead less
A Randomised Trial Of Constraint Induced Movement Therapy And Botulinum Toxin A In Children With Congenital Hemiplegia.
Funder
National Health and Medical Research Council
Funding Amount
$399,995.00
Summary
Congenital hemiplegia occurs in over 1 million children under 21 years of age in the industrialized world. It is the most common type of cerebral palsy, accounting for 36 percent of children diagnosed with this lifelong condition. We intend to determine if a promising new treatment approach is effective in providing a superior and lasting benefit, compared to conventional techniques. Children with hemiplegia usually have the intellectual capacity to attend normal school; however the impaired arm ....Congenital hemiplegia occurs in over 1 million children under 21 years of age in the industrialized world. It is the most common type of cerebral palsy, accounting for 36 percent of children diagnosed with this lifelong condition. We intend to determine if a promising new treatment approach is effective in providing a superior and lasting benefit, compared to conventional techniques. Children with hemiplegia usually have the intellectual capacity to attend normal school; however the impaired arm reduces independence in activities of daily living and can compromise their ability to participate in educational, leisure and vocational roles. Previously we have shown that a program of upper limb rehabilitation in children with spasticity was effective in improving participation and quality of life. We have also shown that rehabilitation combined with Botulinum toxin A (Botox) can further improve functional activity. We believe that a new method of therapy, that has been used effectively in Adults with stroke, called Constraint Induced Movement Therapy (CIMT) may also be beneficial in the treatment of children with congenital hemiplegia. In CIMT, the unimpaired arm is constrained in a glove to promote use of the impaired arm (hemiplegic arm). We predict that, combined with the Botox treatment, CIMT will provide a superior and longer lasting benefit compared to standard rehabilitation combined with Botox. The primary aim of our study is to test this hypothesis in a controlled trial. A secondary aim is to further our understanding of the central neurovascular mechanisms underlying changes in upper limb function. To achieve this, we will use Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS) to measure central activation in the parts of the brain controlling movement. Improving our understanding of the mechanisms involved in this condition is an essential next step towards providing a more effective and long lasting treatment.Read moreRead less
Generating And Applying Clinical Research To Improve The Outcomes Of Neonatal Intensive Care
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Birth is a complex process and sometimes babies require help to make the transition to independent life. Professor Peter Davis is conducting research into how best to support this transition. This involves helping the lungs to work efficiently and supporting the changes in circulation of the blood to the brain and to the rest of the body. His work aims to quickly identify babies who need help and then provide better treatments to make sure they have the best chance of a healthy life.
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less
Immunisation Practice And Policy Development In Australia: Responding To Urgent Priorities In Prevention Of Endemic And Epidemic Infectious Diseases In Children.
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Despite high immunisation coverage rates in Australia deaths still occur in young infants from vaccine preventable diseases such as whooping cough, meningitis and influenza. My research in vaccines and immunisation involves trialing new vaccines such as meningococcal B and H1N1 vaccine to ensure their safety and effectiveness in children and investigation of new ways to deliver vaccines to improve uptake of new vaccines in the community to ensure earlier and better protection for infants and chi ....Despite high immunisation coverage rates in Australia deaths still occur in young infants from vaccine preventable diseases such as whooping cough, meningitis and influenza. My research in vaccines and immunisation involves trialing new vaccines such as meningococcal B and H1N1 vaccine to ensure their safety and effectiveness in children and investigation of new ways to deliver vaccines to improve uptake of new vaccines in the community to ensure earlier and better protection for infants and children against severe infectious diseases.Read moreRead less
Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.